[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100292848":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":50,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Idiopathic inflammatory myopathies 1",null,"Intravenous infusion with methyprednisolone \u002F human intravenous immunoglobulin at disease onset",[13],"Drug: Intravenous Infusion",{"label":15,"type":10,"description":16,"interventionNames":17},"Idiopathic inflammatory myopathies 2","Intravenous infusion with methyprednisolone at disease onset",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Intravenous Infusion","Intravenous infusion of follow medicine at disease onset: methyprednisolone and\u002For human intravenous immunoglobulin",[9,15],[25],"Medicine",[27],{"name":28,"affiliation":29,"role":30},"Samuel K Shinjo, PhD","Universidade de Sao Paulo - Rheumatology Division","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","55-11-3061-7176","samuel.shinjo@gmail.com",[37],{"facility":38,"status":39,"city":40,"state":10,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"Samuel Katsuyuki Shinjo","RECRUITING","São Paulo","01246903","Brazil","BR",{"type":45,"coordinates":46},"Point",[47,48],-46.63611,-23.5475,{"lat":48,"lon":47},{"type":30,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Samuel Katsuyuki Shinjo, PhD","Principal Investigator","100292848","optimizing-treatment-on-idiopathic-inflammatory-myopathies-100292848",false,"NCT03092180","Optimizing Treatment on Idiopathic Inflammatory Myopathies","Inclusion Criteria:\n\n* Idiopathic inflammatory myopathies\n\nExclusion Criteria:\n\n* Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies, overlapped myopathies, others myopathies","ALL","18 Years",{"count":62,"type":63},60,"ESTIMATED","OBSERVATIONAL","As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and\u002For human intravenous immunoglobulin, or only methyprednisolone at disease onset.\n\nThis scheme is an internal routine protocol of our Service.",[67],"Idiopathic Inflammatory Myopathies",[69,70,71,72,73,74,75],"Dermatomyositis","Immunomodulation","Immunosuppressive agents","Myositis","Polymyositis","Necrotizing myopathies","Antisynthetase syndrome","2024-12-04",{"date":78,"type":79},"2024-12-05","ACTUAL",{"date":81,"type":10},"2005-01",{"date":76,"type":63},{"name":5,"class":6},1]